This meta- analysis shows that oral tibolone treatment significantly lowers circulating Lp(a ) levels in postmenopausal women .
INTRODUCTION Circulating lipoprotein ( a ) ( Lp(a ) ) is a recognized risk factor for cardiovascular disease ( CVD ) .
Tibolone , a synthetic steroid , may lower Lp(a ) levels ; however , evidence of the effects of tibolone on Lp(a ) still remain to be defined .
Therefore , we investigated the effects of tibolone treatment on circulating Lp(a ) levels in postmenopausal women .
Effects of either Tibolone or Continuous Combined Transdermal Estradiol with Medroxyprogesterone Acetate on Coagulatory Factors and Lipoprotein(a) in Menopause
Background / Aim : The aim of this prospect i ve controlled study was to compare the effects of two therapies for menopause on factor VII ( FVII ) and hemostatic variables . Methods : Postmenopausal women were assigned to receive one of the following treatments : transdermal estradiol ( TTS E2 ; 50 μg ) combined in a continuous sequential regimen with oral medroxyprogesterone acetate ( MPA ; 10 mg/day for 12 days ) ( group A ; n = 20 ) , tibolone ( 2.5 mg/day ) ( group B ; n = 21 )  or placebo  ( group C ; n = 19 ) . Sixty women completed the 1-year treatment and underwent follow-up examinations after 3 , 6 and 12 months . Results : TTS E2/MPA induced various changes in procoagulatory factors . At 12 months , fibrinogen , activated FVII ( FVIIa ) and coagulative FVII ( FVIIc ) had increased by 10.7 , 12.9 and 3.7 % , respectively . Among the fibrinolytic factors , plasminogen and α2-antiplasmin increased by 11.3 and 7.2 % , respectively . Lipoprotein(a ) [ Lp(a ) ] and antithrombin III ( ATIII ) did not show any significant variation . Tibolone induced some changes toward a more homogeneous antithrombotic profile . Fibrinogen , FVIIa and FVIIc decreased significantly by 7.5 , 8.1 and 21.3 % , respectively . Plasminogen increased ( by 11.8 % ) and Lp(a ) decreased ( by 28.4 % ) . ATIII was unchanged with tibolone therapy . Conclusion : Our results show that tibolone induces a significant reduction in FVIIc and Lp(a ) and a greater enhancement of factors promoting fibrinolysis than the TTS E2/MPA regimen
This meta- analysis shows that oral tibolone treatment significantly lowers circulating Lp(a ) levels in postmenopausal women .
INTRODUCTION Circulating lipoprotein ( a ) ( Lp(a ) ) is a recognized risk factor for cardiovascular disease ( CVD ) .
Tibolone , a synthetic steroid , may lower Lp(a ) levels ; however , evidence of the effects of tibolone on Lp(a ) still remain to be defined .
Therefore , we investigated the effects of tibolone treatment on circulating Lp(a ) levels in postmenopausal women .